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Smnmary: The objective of this study was to invcstigate the role of the MET oncogene in canine osteosar- 
coma. Seven large-brccd dogs affected by spontaneous skeletal osteosarcoma underwent en bloc tumor exci- 
sion. Total RNA was extracted from frozen tumor samples and assessed for expression of the MET oncogene 
by Northern blot analysis. Fivc of seven biopsy samples cxpressed high Ievels of the MET oncogene; its ex- 
pression in the primary tumors was comparable with that previously identified in primary osteosarcomas in 
humans. A lung metastasis from one of the dogs expressed MET at a higher level than did its primary tumor. 
Spontaneously arising osteosarcoma in dogs clinically and pathologically mimics the corresponding disease 
in humans. We previously demonstrated that the MET oncogene was aberrantly expressed in a high percent- 
age of human osteosarcomas. The results of the current study also providc a molecular parallel between the 
tumors in dogs and humans. This in vivo model may he helpful in evaluating new strategies for therapy 
against osteosarcoma. 
Osteosarcoma of the appendicular skeleton is one 
of the most life-threatcning canine neoplasms. It is 
typically found in middle-aged, large-breed male 
dogs. Osteosarcoma most commonly involves the 
metaphysis of any long bone (except near the elbow), 
with the distal radius being the most common ana- 
tomic site (Fig. 1A). The pathogenesis of canine 
osteosarcoma is not completely understood; one pre- 
disposing factor is excessive body weight and its inci- 
dence appears to be increased in certain family lincs 
of large-breed dogs (3). Canine osteosarcoma has the 
samc biological behavior as its human counterpart 
(28) (Fig. 1 B) and historically has been used as an ex- 
perimental model for therapeutic regimens to be ap- 
plied to the disease in humans (4,13,28). For example, 
the literature suggests that micrometastatic disease is 
present in approximately 90% of dogs at presenta- 
tion. When possible, canine osteosarcoma is treated 
with both aggressive surgery (5,25) and adjuvant che- 
motherapy (1,161. Approximately 50% of dogs sur- 
vive to 1 year after treatment with this combined 
approach. 
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Recent studies investigating the molecular basis of 
tumor cell invasion and metastasis have identified 
novel therapeutic approaches based on targeting al- 
terations in normal cellular pathways (12). The MET 
oncogenc has been shown to play an important role 
in these phenotypic changes (7,15,17). It has been 
overexpressed or has mutated, or both, in different 
sporadic and hereditary human carcinomas (20). Its 
involvement has also been documented as sarcoma- 
genesis (9,18,21). The MET proto-oncogene is the 
receptor for the cytokine hepatocyte growth factor/ 
scatter factor (HGF), which stimulates the invasive 
growth of normal and neoplastic cells (9,10,27). In 
physiological conditions, MET is expressed in cells of 
epithelial origin whereas its ligand, HGF, is expressed 
in cells of mesenchymal origin (23). 
We previously demonstrated that the MET onco- 
gene was aberrantly expressed in several cases of 
spontaneous osteosarcomas in humans (9), cell lines 
of the same origin, and a number of other aggressive 
mesenchymal neoplasms (21). Moreover, in vitro 
studies demonstrated that osteosarcoma cell lines ac- 
quired an invasive phenotype when HGF was added 
to the culture medium; this further implicates MET in 
the invasive potential of these tumors (9). 
Because of the strong clinical and biological anal- 
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FIG. 1. An osteoblastic osteosarcoma ol the distal radius of a 
4-year-old malc Newfoundland Retriever (Table 1, dog 3). A 
Standard radiograph. B: Histologic slide of the tumor stained 
with hematoxylin and eosin. Note the abundant osteoid matrix. 
Histologically, this canine tumor cannot be distinguished from 
its human counterpart. 
assumed that similarities were also present at the 
molecular level. this study, we demonstrated that 
the MET oncogene was frequently expressed at high 
levels in spontaneous canine osteosarcoma. 
bccn previously confirmed by immunohistochemistry and West- 
ern blotting with specific anti-HGF receptor monoclonal antibod- 
ies (21). 
RESULTS 
MATERIALS AND METHODS 
Seven large-breed dogs were diagnosed with skeletal osteosar- 
coma on the basis of standard radiographs and histologic evalua- 
tion of biopsy samples following tumor excision. The mean age was 
7.2 years, and the mean weight was 32 kg. Six dogs had localized 
disease, and one had a solitary lung metastasis at the time of pre- 
sentation of a primary rib lesion. The dogs had not received treat- 
ment for the disease, and all were healthy at the time of diagnosis. 
The dogs underwent wide resection of the primary tumor with 
limb-sparing techniques when applicable (25); the dog with the 
lung metastasis had this lesion resected at the same time as the 
primary tumor. Each animal also received adjuvant chemotherapy 
with doxorubicin at the standard dose (2). Following each surgical 
procedure, a tumor sample was snap-frozen in liquid nitrogen 
while an adjacent tumor specimen was examined pathologically 
to confirm the presence of viable osteosarcoma. 
The D17 canine and MG63 human osteosarcoma cell lines were 
obtained from the American Tissue Culture Collection (refcrence 
nos. CLL183 and CRL1427; ATCC, Rockville, MD, U.S.A.). Sam- 
ples of osteosarcoma were obtained from humans as previously 
described (9). Total RNA was extracted from thc frozen tumor 
samples and cell lines by the TRI REAGENT method (Sigma 
Chemical, St. Louis. MO, U.S.A.) (6) and was quantified by spec- 
trophotometry. Fourteen micrograms of RNA from each sample 
was separated by agarose gel electrophoresis, stained with ethid- 
ium bromide, and photographed for densitometry. Northern blot 
analysis was initially performed (19) with a full-length human 
MET cDNA probe (9). Subsequently, a glyceraldehyde phosphate 
dehydrogenase full-length probe was used as an internal control 
for the quantity and quality of RNA loaded per sample. The level 
of expression of MET compared with that of glyceraldehyde phos- 
phate dehydrogenase was expressed in arbitrary units relative to 
a human osteosarcoma biopsy sample that was chosen as a posi- 
tive control, MET expression in this standard positive control had 
Total RNA from eight canine osteosarcoma tumor 
samples and the D17 canine osteosarcoma cell line 
were analyzed by Northern blot analysis for MET ex- 
pression (Fig. 2). Five of seven osteosarcoma biopsy 
samples and the D17 cell line were positive for ex- 
pression of the MET oncogene (Table 1). The fi- 
broblastic and chondroblastic osteosarcomas had no 
detectable expression of MET compared with the 
other subtypes seen on histology. The level of MET 
expression in the canine tumor samples was compara- 
ble with that in a human osteosarcoma chosen as a 
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FIG. 2. Northern blot analysis of MET cxpression in canine os- 
teosarcoma. Lane A: D17 canine osteosarcoma cell line overex- 
pressing MET. Lane B: negative control, normal skcletal muscle. 
Lane C: negative control, normal tissue from the margin of the sur- 
gical excision of the tumor shown in lane D. Lanes D, E, and G: ca- 
nine osteosarcomas. Lane F: canine fihrosarcoma; this sample did 
not contain a significant amount of RNA. Lane H: standard posi- 
tive control from a human osteosarcoma. Lane I: MC63 human os- 
teosarcoma cell line. The upper row shows the internal control 
gene glyceraldehyde phosphate dehydrogenase (GAPDH), and 
the lower row shows ievels of MET expression. 
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TABLE. 1. Histological appearance 
of tumors and expression o.f MET 
Histological 

















“The arbitrary level of MET expression denoted by + is similar 
to the level identified in the standard positive control from a human 
osteosarcoma (Fig. 2, lane H). 
standard positive control (Fig. 2, lane H), as well as in 
the human MG63 osteosarcoma ceIl line (Fig. 2, lane 
I) (9). The lung metastasis from dog 2 expressed MET 
at a higher level than its corresponding primary tu- 
mor (Fig. 2, lane G). In fact, the metastasis was the 
only tumor specimen to exhibit MET expression at 
the ++ level (Table 1). N o  correlation was found be- 
tween MET expression and the outcome for the dogs. 
All but one dog died of lung metastases in a period 
between 5 and 14 months. The surviving animal was 
alive and disease-free at 35 months follow-up (Table 
1, dog 6). Dog 4 (Table 1) did not receive treatment. 
All the remaining animals underwent surgery and 
chemotherapy. 
DISCUSSION 
Specific types of canine malignancies are similar to 
their human counterparts in histopathologic appear- 
ance, biological behavior, and response to therapy. 
Naturally occurring osteosarcoma in dogs represents 
a typical model for the disease in humans. Despite re- 
cent advances in surgical techniques and chemother- 
apy protocols, humans with osteosarcoma continue to 
have a guarded prognosis due to the high risk of sys- 
temic recurrence, which occurs in more than 40% of 
the cases (22). In the canine counterpart, despite ag- 
gressive surgery and chemotherapy, most dogs die 
within 2 years due to the shorter latency period of the 
disease (24). There is an evident need to increase our 
knowledge of the molecular characteristics underly- 
ing the disease in humans and dogs. 
The results of this study verified in the dog model 
a molecular observation we pi-eviously described in 
human osteosarcoma regarding the aberrant expres- 
sion of the MET oncogene (21). In terms of analogies 
of MET function in normal cells, it was previously 
shown that canine epithelial cells, which express the 
MET receptor, respond to the human ligand HCF in 
vitro (8,27) and in v ivo  (14). Furthermore, HGF is 
ubiquitous in connective tissues and surgical samples 
of human osteosarcoma (9). These findings suggest 
that MET receptor function is maintained in both 
species under normal physiological conditions, as 
well as in malignancy. 
The MET oncogene, which plays an important role 
in tumor invasion and metastasis in several carcino- 
mas and sarcomas in humans and experimental ani- 
mals (9), was expressed at high levels in canine 
osteosarcoma. The number of tumors that overex- 
pressed MET was also comparable with that for the 
human counterpart (21). Interestingly, the lung me- 
tastasis had a higher MET level than did any of the 
primary tumors. This further supports the role of this 
oncogene in the processes of invasion and metastasis. 
Similar to the human model of osteosarcoma, the 
chondroblastic and fibroblastic subtypes of the dis- 
ease in dogs were negative for MET expression. 
These data also correlate with the virtual absence of 
MET expression in most chondroid and fibroblastic 
benign and malignant tumors in humans (21). No cor- 
relation was found between MET expression and 
clinical outcome. This might be due to the dismal 
prognosis of this disease in dogs, regardless of the 
therapeutic efforts (23). 
This study provides an encouraging step in the com- 
parison of human and canine osteosarcoma on a mo- 
lecular level. On the basis of the evidence, we expect 
the MET oncogene to play as important a role in the 
canine system as in its human counterpart. These 
data, although preliminary, are promising in terms of 
the development of new diagnostic and therapeutic 
approaches in veterinary medicine and for the en- 
hancement of comparative oncology in osteosarcoma. 
Novel interventional strategies-developed in vitro 
and in laboratory studies in animals-for modulating 
MET expression and receptor function can be tested 
in vivo in dogs with spontaneously occurring tumors. 
Similar studies might be unacceptable or less feasible 
in humans with cancer, especially because a standard, 
yet only partially effective, treatment exists. 
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